SKYRIZI™ (risankizumab-rzaa) Now Available From BioPlus Specialty Pharmacy for Moderate to Severe Plaque Psoriasis

SKYRIZI™ (risankizumab-rzaa) Now Available From BioPlus Specialty Pharmacy for Moderate to Severe Plaque Psoriasis

BioPlus Specialty Pharmacy (BioPlus), one of the nation’s leading innovative specialty pharmacies, is pleased to announce that it is one of the specialty pharmacies now dispensing the newly approved medication SKYRIZI™ (risankizumab-rzaa) from AbbVie. SKYRIZI received approval from the U.S. Food and Drug Administration (FDA) on April 23, 2019 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

SKYRIZI targets and binds to interleukin 23 (IL-23), a protein that is involved in inflammatory and immune responses. It is administered by two subcutaneous injections every 12 weeks, following two initiation doses at week 0 and 4. 

“BioPlus is ready to dispense SKYRIZI, which provides patients a new treatment option for relieving the discomfort of psoriasis,” explains Sharon Ferrer, VP of Pharmaceutical Relations at BioPlus. “With our extensive experience with immune-mediated conditions as a specialty pharmacy, BioPlus brings trusted care for patients starting treatment with SKYRIZI, while our RxExpress program gets patients started quickly on treatment,” she adds. 

The FDA approval of SKYRIZI came after clinical trials showed that people treated with this medication (dosed at weeks 0, 4 and every 12 weeks thereafter) achieved a high level of psoriasis clearance. 

As an immune-mediated disease, psoriasis primarily affects the skin. There are several forms of psoriasis, with plaque psoriasis being the most common. In plaque psoriasis, there are thick, red areas on the skin that become flaky with silver-white scales. This disease tends to run in families. 

Share this article

Share on facebook
Share on twitter
Share on linkedin
Share on email
Scroll to Top